Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?
FDA Law Blog
JUNE 23, 2021
For example, we know that cancer patients have a high tolerance for toxicity when offered a chance at improved survival, a risk tolerance that would not be shared by individuals suffering from the common cold. FDA Announces Final PFDD Meetings, and BIO Recommends Broader Use of the Benefit-Risk Framework (July 1, 2015). 13, 2014).
52 
Let's personalize your content